ArticleAnnals of neurology2022
Reduced Numbers of Corticotropin-Releasing Hormone Neurons in Narcolepsy Type 1.
Article in Annals of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Postmortem Evidence of CRH Neuron Reduction in Narcolepsy Without Cataplexy With Borderline Hypocretin-1 Levels.Journal of sleep research · 2026Article
- Narcolepsy is (not) an autoimmune disease.Nature reviews. Neurology · 2026Review
- Increased Numbers of CD4Annals of neurology · 2026Article
- Human narcolepsy is linked to degeneration of both locus coeruleus and hypocretin neurons.Nature communications · 2026Article
- Cytokines in narcolepsy type 1: pathogenic relevance, biomarker potential, and future directions.Frontiers in neurology · 2026Review
- Narcolepsy: Pathophysiology, Diagnosis, Management, and Future Directions, a Narrative Review.Brain and behavior · 2025Review
- Integrative sleep management: from molecular pathways to conventional and herbal treatments.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Present and Future of Central Disorders of Hypersomnolence.Journal of sleep research · 2025Review
- The paraventricular nucleus of the hypothalamus: a key node in the control of behavioural states.The Journal of physiology · 2025Review
- Dissociation of subjective and physiological stress responses in orexin-deficient narcolepsy.Sleep · 2025Article
- Article
- The Role of T Cells in the Pathogenesis of Narcolepsy Type 1: A Narrative Review.International journal of molecular sciences · 2024Review
- White matter integrity in narcolepsy: the structural blueprint for functional complaints?Sleep · 2024Article
- Predicting Depression Among Chinese Patients with Narcolepsy Type 1: A Machine-Learning Approach.Nature and science of sleep · 2024Article
- The Changed Nocturnal Sleep Structure and Higher Anxiety, Depression, and Fatigue in Patients with Narcolepsy Type 1.Nature and science of sleep · 2024Article
- Analysis of thyroid function and related factors in narcolepsy patients.Scientific reports · 2023Article
- Article
- Epigenetic silencing of selected hypothalamic neuropeptides in narcolepsy with cataplexy.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Article
- Cerebrospinal fluid proteomics in recent-onset Narcolepsy type 1 reveals activation of the complement system.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Narcolepsy type 1 (NT1) is a chronic sleep disorder correlated with loss of hypocretin(orexin). In NT1 post-mortem brains, we observed 88% reduction in corticotropin-releasing hormone (CRH)-positive neurons in the paraventricular nucleus (PVN) and significantly less CRH-positive fibers in the median eminence, whereas CRH-neurons in the locus coeruleus and thalamus, and other PVN neuronal populations were spared: that is, vasopressin, oxytocin, tyrosine hydroxylase, and thyrotropin releasing hormone-expressing neurons. Other hypothalamic cell groups, that is, the suprachiasmatic, ventrolateral preoptic, infundibular, and supraoptic nuclei and nucleus basalis of Meynert, were unaffected. The surprising selective decrease in CRH-neurons provide novel targets for diagnostics and therapeutic interventions. ANN NEUROL 2022;91:282-288.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.